JP2012502099A - Ｃ型肝炎の治療のための化合物 - Google Patents

Ｃ型肝炎の治療のための化合物 Download PDF

Info

Publication number
JP2012502099A
JP2012502099A JP2011526911A JP2011526911A JP2012502099A JP 2012502099 A JP2012502099 A JP 2012502099A JP 2011526911 A JP2011526911 A JP 2011526911A JP 2011526911 A JP2011526911 A JP 2011526911A JP 2012502099 A JP2012502099 A JP 2012502099A
Authority
JP
Japan
Prior art keywords
solvent
alkyl
phenyl
hydrogen
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502099A5 (cg-RX-API-DMAC7.html
Inventor
リチャード・プラシット
ジョン・エフ・カドウ
ジョン・エイ・ベンダー
ブレット・アール・ベノ
キャサリン・エイ・グラント−ヤング
イン・ハン
ピヤセナ・ヘワワサム
アンドリュー・ニッケル
カイル・イー・パーセラ
カプ−スン・イェウン
ルイス・エス・チュパク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2012502099A publication Critical patent/JP2012502099A/ja
Publication of JP2012502099A5 publication Critical patent/JP2012502099A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011526911A 2008-09-11 2009-09-02 Ｃ型肝炎の治療のための化合物 Pending JP2012502099A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9600408P 2008-09-11 2008-09-11
US61/096,004 2008-09-11
PCT/US2009/055648 WO2010030538A2 (en) 2008-09-11 2009-09-02 Compounds for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
JP2012502099A true JP2012502099A (ja) 2012-01-26
JP2012502099A5 JP2012502099A5 (cg-RX-API-DMAC7.html) 2012-10-11

Family

ID=41203516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526911A Pending JP2012502099A (ja) 2008-09-11 2009-09-02 Ｃ型肝炎の治療のための化合物

Country Status (10)

Country Link
US (2) US8198449B2 (cg-RX-API-DMAC7.html)
EP (1) EP2331502B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012502099A (cg-RX-API-DMAC7.html)
KR (1) KR20110056537A (cg-RX-API-DMAC7.html)
CN (2) CN103864783A (cg-RX-API-DMAC7.html)
AR (1) AR073586A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009291993A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011002471A (cg-RX-API-DMAC7.html)
TW (1) TW201014855A (cg-RX-API-DMAC7.html)
WO (1) WO2010030538A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500705A (ja) * 2012-11-05 2016-01-14 バイエル・ファルマ・アクティエンゲゼルシャフト アミノ置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用
JP2016540745A (ja) * 2013-11-12 2016-12-28 ダウ アグロサイエンシィズ エルエルシー 化合物をフッ素化するための方法
JP2017529401A (ja) * 2014-09-26 2017-10-05 チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
EP3257854A1 (en) * 2009-11-05 2017-12-20 University of Notre Dame du Lac Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
US8324212B2 (en) * 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011112186A1 (en) * 2010-03-10 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
US8324239B2 (en) * 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2012051659A1 (en) * 2010-10-20 2012-04-26 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
CN103269586B (zh) 2010-10-26 2015-07-15 普雷西迪奥制药公司 丙型肝炎病毒抑制剂
JP5918264B2 (ja) * 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
EA027418B1 (ru) 2011-06-27 2017-07-31 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
NZ628515A (en) 2012-02-10 2016-06-24 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
EP2831066B1 (en) 2012-03-27 2016-10-05 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
US8785478B2 (en) 2012-04-11 2014-07-22 Biota Scientific Management Pty Ltd. Viral polymerase inhibitors
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
CN102690264B (zh) * 2012-06-20 2014-07-02 泰山医学院 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
KR102171706B1 (ko) 2012-07-09 2020-10-30 얀센 파마슈티카 엔.브이. 포스포디에스테라아제 10 효소의 억제제
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
PT2925757T (pt) 2012-11-19 2018-01-09 Novartis Ag Compostos e composições para o tratamento de doenças parasitárias
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US8962651B2 (en) * 2013-03-13 2015-02-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CA2939793A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
KR20160126085A (ko) * 2014-03-21 2016-11-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염의 치료를 위한 시아노 함유 아자벤조푸란 화합물
US9771360B2 (en) 2014-03-21 2017-09-26 Bayer Pharma Aktiengesellschaft Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use
WO2015143256A1 (en) * 2014-03-21 2015-09-24 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
CN106459037A (zh) 2014-05-02 2017-02-22 拜耳医药股份有限公司 用于治疗心血管疾病的N‑(2‑氨基‑5‑氟‑2‑甲基戊基)‑8‑[(2,6‑二氟苄基)氧基]‑2‑甲基咪唑并[1,2‑a]吡啶‑3‑甲酰胺的对映异构体及其二‑和三氟衍生物的对映异构体
US9957278B2 (en) * 2014-08-05 2018-05-01 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis C
EP3227287B1 (de) 2014-12-02 2019-08-07 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
RU2019123849A (ru) 2019-07-29 2021-02-01 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Ингибиторы фактора ингибирования миграции макрофагов
WO2024102699A1 (en) * 2022-11-07 2024-05-16 ELANCO US, Inc. Guanylate cyclase (gc) stimulator formulations and uses thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502707A (en) * 1967-09-11 1970-03-24 Mcneilab Inc Beta-(cyclohexyl and substituted phenyl)-alpha-(4,5-dimethoxy-2-nitro- or aminophenyl) acrylonitriles
JPS57123181A (en) * 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
JPH06234667A (ja) * 1992-10-29 1994-08-23 Hoechst Ag 芳香族ブロモメチル化合物の製造方法
JP2001526286A (ja) * 1997-12-19 2001-12-18 イーライ・リリー・アンド・カンパニー 低血糖性イミダゾリン化合物
JP2004506736A (ja) * 2000-08-22 2004-03-04 グラクソ　グループ　リミテッド タンパク質キナーゼ阻害剤としての縮合ピラゾール誘導体
JP2004507542A (ja) * 2000-08-28 2004-03-11 藤沢薬品工業株式会社 ピラゾロピリジン化合物およびその医薬
JP2004525150A (ja) * 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
JP2005530788A (ja) * 2002-05-13 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類
JP2006510736A (ja) * 2002-11-01 2006-03-30 バイロファーマ・インコーポレイテッド ベンゾフラン化合物、組成物およびｃ型肝炎感染症および関連疾患の治療または予防方法
WO2008082490A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2008100867A2 (en) * 2007-02-12 2008-08-21 Intermune, Inc. Novel inhibitors hepatitis c virus replication
JP2008247878A (ja) * 2007-03-30 2008-10-16 Maruishi Pharmaceutical Co Ltd イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200528459A (en) * 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JPWO2007069565A1 (ja) 2005-12-12 2009-05-21 小野薬品工業株式会社 二環式複素環化合物
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
EP2245023B1 (en) 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502707A (en) * 1967-09-11 1970-03-24 Mcneilab Inc Beta-(cyclohexyl and substituted phenyl)-alpha-(4,5-dimethoxy-2-nitro- or aminophenyl) acrylonitriles
JPS57123181A (en) * 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
JPH06234667A (ja) * 1992-10-29 1994-08-23 Hoechst Ag 芳香族ブロモメチル化合物の製造方法
JP2001526286A (ja) * 1997-12-19 2001-12-18 イーライ・リリー・アンド・カンパニー 低血糖性イミダゾリン化合物
JP2004506736A (ja) * 2000-08-22 2004-03-04 グラクソ　グループ　リミテッド タンパク質キナーゼ阻害剤としての縮合ピラゾール誘導体
JP2004507542A (ja) * 2000-08-28 2004-03-11 藤沢薬品工業株式会社 ピラゾロピリジン化合物およびその医薬
JP2004525150A (ja) * 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
JP2005530788A (ja) * 2002-05-13 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類
JP2006510736A (ja) * 2002-11-01 2006-03-30 バイロファーマ・インコーポレイテッド ベンゾフラン化合物、組成物およびｃ型肝炎感染症および関連疾患の治療または予防方法
WO2008082490A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2008100867A2 (en) * 2007-02-12 2008-08-21 Intermune, Inc. Novel inhibitors hepatitis c virus replication
JP2008247878A (ja) * 2007-03-30 2008-10-16 Maruishi Pharmaceutical Co Ltd イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5011012619; ＥＬＳＮＥＲ　Ｊ: 'ＢＩＣＹＣＬＩＣ　ＭＥＬＡＴＯＮＩＮ　ＲＥＣＥＰＴＯＲ　ＡＧＯＮＩＳＴＳ　ＣＯＮＴＡＩＮＩＮＧ　Ａ　ＲＩＮＧ-ＪＵＮＣＴＩＯＮ　ＮＩＴＲＯＧＥＮ：　以下備考' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖ１４　Ｎ６, 20060315, Ｐ１９４９-１９５８, ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＣＥ　ＬＴＤ *
JPN5011012620; ＫＡＫＥＨＩ，　ＡＫＩＫＡＺＵ: 'ＰＲＥＰＡＲＡＴＩＯＮ　ＯＦ　ＮＥＷ　ＮＩＴＲＯＧＥＮ-ＢＲＩＤＧＥＤ　ＨＥＴＥＲＯＣＹＣＬＥＳ．　ＸＩＶ．　ＦＵＲＴＨＥＲ　ＩＮＶＥＳＴＩＧＡＴＩＯＮ　以下備考' ＣＨＥＭＩＣＡＬ　＆　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ　ＢＵＬＬＥＴＩＮ Ｖ３５　Ｎ１, 1987, Ｐ１５６-１６９ *
JPN5011012621; ＭＩＫＩ，　ＹＡＳＵＹＯＳＨＩ: 'ＡＣＩＤ-ＣＡＴＡＬＹＺＥＤ　ＲＥＡＣＴＩＯＮＳ　ＯＦ　３-（ＨＹＤＲＯＸＹＭＥＴＨＹＬ）-　ＡＮＤ　３-（１-ＨＹＤＲＯＸＹＥＴＨＹＬ）ＰＹＲＡＺＯＬＯ［１，５-ａ］ＰＹＲＩＤＩＮＥＳ' ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＨＥＭＩＳＴＲＹ Ｖ２６　Ｎ６, 1989, Ｐ１７３９-１７４５ *
JPN5011012622; ＤＩ　ＣＨＩＡＣＣＨＩＯ，　ＡＮＮＡ: 'ＲＥＳＥＡＲＣＨ　ＯＮ　ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＯＭＰＯＵＮＤＳ，　ＰＡＲＴ　４０．　２-ＰＨＥＮＹＬＩＭＩＤＡＺＯ［１，２-ａ］ＰＹＲＩＤＩＮＥ-以下備考' ＡＲＣＨＩＶ　ＤＥＲ　ＰＨＡＲＭＡＺＩＥ Ｖ３３１　Ｎ９, 1998, Ｐ２７３-２７８ *
JPN5011012623; ＫＡＴＡＧＩＲＩ，　ＮＯＢＵＹＡ: 'ＳＴＵＤＩＥＳ　ＯＦ　ＫＥＴＥＮＥ　ＡＮＤ　ＩＴＳ　ＤＥＲＩＶＡＴＩＶＥＳ．　ＰＡＲＴ　１１９［１］．　ＲＥＡＣＴＩＯＮＳ　ＯＦ　ＨＡＬＯＫＥＴＥＮＥＳ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＨＥＭＩＳＴＲＹ Ｖ２１　Ｎ２, 1984, Ｐ４０７-４１２ *
JPN5011012624; ＡＢＩＧＮＥＮＴＥ　Ｅ: 'ＲＥＳＥＡＲＣＨ　ＯＮ　ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＯＭＰＯＵＮＤＳ．　ＸＸＩＩＩ．　ＰＨＥＮＹＬ　ＤＥＲＩＶＡＴＩＶＥＳ　ＯＦ　ＦＵＳＥＤ　ＩＭＩＤＡＺＯＬＥ　ＳＹＳＴＥＭＳ' ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＨＥＭＩＳＴＲＹ Ｖ２６, 19891101, Ｐ１８７５-１８８０, ＷＩＬＥＹ-ＢＬＡＣＫＷＥＬＬ　ＰＵＢＬＩＳＨＩＮＧ，　ＩＮＣ *
JPN5011012625; ＴＲＡＰＡＮＩ　Ｇ: 'ＳＹＮＴＨＥＳＩＳ　ＡＮＤ　ＢＩＮＤＩＮＧ　ＡＦＦＩＮＩＴＹ　ＯＦ　２-ＰＨＥＮＹＬＩＭＩＤＡＺＯ［１，２-ａ］ＰＹＲＩＤＩＮＥ　ＤＥＲＩＶＡＴＩＶＥＳ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖ４０, 19970101, Ｐ３１０９-３１１８, ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＣＩＥＴＹ *
JPN7014000590; ＳＴＮ　ＯＮ　ＴＨＥ　ＷＥＢ，　ＦＩＬＥ　ＲＥＧＩＳＴＲＹ，　ＲＮ＝１０２７１８０-２０-６，９５９５７７-６８-５，８８７５９０-０５-８，８７３９４３-８２-９ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500705A (ja) * 2012-11-05 2016-01-14 バイエル・ファルマ・アクティエンゲゼルシャフト アミノ置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用
JP2016540745A (ja) * 2013-11-12 2016-12-28 ダウ アグロサイエンシィズ エルエルシー 化合物をフッ素化するための方法
JP2017529401A (ja) * 2014-09-26 2017-10-05 チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体
US10100027B2 (en) 2014-09-26 2018-10-16 Changzhou Yinsheng Pharmaceutical Co., Ltd. Benzofuran analogue as NS4B inhibitor

Also Published As

Publication number Publication date
CN102209711B (zh) 2014-06-18
AR073586A1 (es) 2010-11-17
CN103864783A (zh) 2014-06-18
EP2331502A2 (en) 2011-06-15
MX2011002471A (es) 2011-04-05
US8536338B2 (en) 2013-09-17
US8198449B2 (en) 2012-06-12
WO2010030538A3 (en) 2010-05-06
US20100063068A1 (en) 2010-03-11
AU2009291993A1 (en) 2010-03-18
WO2010030538A2 (en) 2010-03-18
CN102209711A (zh) 2011-10-05
TW201014855A (en) 2010-04-16
EP2331502B1 (en) 2016-03-02
US20120232099A1 (en) 2012-09-13
KR20110056537A (ko) 2011-05-30

Similar Documents

Publication Publication Date Title
JP5572725B2 (ja) Ｃ型肝炎の処置のための化合物
JP2012502099A (ja) Ｃ型肝炎の治療のための化合物
US8293909B2 (en) Compounds for the treatment of hepatitis C
EP2326633B1 (en) Compounds for the treatment of hepatitis c
JP4602076B2 (ja) 抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物
US8546376B2 (en) Pharmaceutical compounds
JP5735551B2 (ja) Ｃ型肝炎の処置のための化合物
AU2015289643A1 (en) Therapeutic inhibitory compounds
CN105732614B (zh) 磺酰胺基芳基炔类化合物及其用途
JP2009520735A (ja) 抗ウイルス性２−カルボキシ−チオフェン化合物
JP2018509401A (ja) Ｃ型肝炎の治療のための新規化合物
WO2008043791A2 (en) Thiophene derivatives for treating hepatitis c
CN102858777B (zh) 治疗丙型肝炎的吡唑并哒嗪衍生物
KR20250017244A (ko) 플라비바이러스 저해제
CN101980711B (zh) 芳族杂环稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
CN101981038A (zh) 二氧戊环和二氧戊环酮稠合的吲哚并苯并二氮杂hcv ns5b抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805